Der er ikke observeret signifikante farmakokinetiske eller farmakodynamiske interaktioner ved samtidig administration af irbesartan og warfarin, et lægemiddel som metaboliseres af CYP2C9. ###>No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9.